Introduction
============

Toxoplasmosis, caused by the protozoan parasite *Toxoplasma gondii*, is one of the most common parasitic infections of human and other warm-blooded animals. Nearly one-third of world populations have been exposed with this parasite ([@B1]). Human, typically, can be infected by three main routes of transmission: ingestion of tissue cysts in raw or undercooked infected meat, ingestion of food or water contaminated with sporulated oocysts shed in the feces of an infected cat and congenitally, vertical transmission from mother to fetus across the placenta ([@B2]). At present, the first choice midication to treat toxoplasmosis is combination of pyrimethamine and sulfadiazine. However, these medications have some drawbacks, because they may have some side effects including osteoporosis, sepsis and teratogenic effects especially in patients with severe disorders of the immune system such as AIDS patients ([@B3], [@B4]). These reasons indicate the urgent needs for development of new medications or combination therapy for treatment of toxoplasmosis.

Historically, natural products and their compounds have been the most productive source for treatment a wide range of diseases, such as infectious diseases ([@B5]). *Bunium persicum* (Boiss), called in Persian as "Zireh Kohi" belongs to Apiaceae family, which widely grows in the southeast of Iran ([@B6]). The plant seeds have been traditionally used as carminative, anti-spasmodic, increasing breast milk and antiepileptic treatment ([@B7]). Reviews have also reported antinociceptive, antioxidant, anti-inflammatory and antimicrobial effects of the *B. persicum* essential oil ([@B8]--[@B10]).

To date, no study has been conducted on the anti-*Toxoplasma* effects this plant. Therefore, the present study was aimed to evaluate the prophylactic and therapeutic efficacy of *B. persicum* essential oil on infected mice with acute toxoplasmosis.

Materials and Methods
=====================

Plant material
--------------

The seeds of *B. persicum* were collected in July 2013, from the wild plants, which grow in the Koohpayeh, Kerman, Iran. The taxonomic identification of the plant was confirmed by Dr. Mozaffarian, Department of Botany of the Research Institute of Forests and Rang-lands (TARI), Tehran, Iran. A voucher specimen (KF 1141) was deposited in the Herbarium Center of the Kerman Faculty of Pharmacy, Kerman, Iran.

Extraction/isolation of the essential oil
-----------------------------------------

Air-dried plant materials (100 g) were subjected to hydro-distillation for 4 h using an all-glass Clevenger-type apparatus. The essential oil obtained was dried over anhydrous sodium sulfate and stored in darkness at 2--8 °C in airtight glass vials closed under nitrogen gas until testing. For the preparation of dilutions of the *B. persicum*, the essential oil was dissolved in olive oil as solvent ([@B11]).

Gas chromatography/mass spectrometry analysis
---------------------------------------------

GC analysis of the *B. persicum*, the essential oil was carried out by a Shimadzu QP 5000 (FID) chromatograph HP-5 MS capillary column (30 m × 0.25 mm, film thickness 0.25 μm). Helium was used as carrier gas at a flow rate 1 ml/min (split ratio 1:20) with injection volume of 0.2 μL. Injector and detector temperatures were set at 220 and 290 °C, respectively. Oven temperature was kept at 50 °C for 3 min, gradually raised to 160 °C at 3 °C/min, held for 10 min and finally raised to 240 °C at 3 °C/min. GC/MS analysis was carried out using a Shimadzu QP 5050 operating at 70 eV ionization energy, equipped with an HP-5 capillary column (phenyl methyl siloxane, 30 m × 0.25 mm, 0.25 μm film thickness) with Helium as the carrier gas (split ratio 1:20). Retention indices were determined by using retention times of *n*-alkanes that had been injected after the oil under the same chromatographic conditions. The components were identified based on the comparison of their relative retention time and mass spectra with those of standards, Wiley 2001 library data of the GC/MS system and literature data ([@B12]).

Parasite
--------

The virulent RH strain of *T. gondii* was obtained from the Parasitology Laboratory at the Department of Parasitology and Mycology, Kerman University of Medical Sciences, Kerman, Iran. Tachyzoites of this strain were collected by serial intraperitoneal passages in mice. Parasites (1×10^4^) were inoculated in the mice, and after 72 h, tachyzoites were provided by repeated flushing of the peritoneal cavity by Phosphate Buffered Saline (PBS). Tachyzoites were then harvested and recovered with PBS and used in the experiments.

Animals
-------

Sixty four male NMRI mice (6--8 weeks old) weighing from 20 to 25 g for establishing animal model of *T. gondii* were obtained from the Pasteur Institute, Tehran, Iran. Animals were housed in a colony room with a 12:12 h light/dark cycle at 21 ± 2 °C and were handled according to standard protocols for the use of laboratory animals. They were divided into eight groups; every group contained eight mice ([Fig. 1](#F1){ref-type="fig"}).
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This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.

The protocol was approved by the Committee on the Ethics of Animal Experiments of the Kerman University of Medical Science (Permit Number: 93/110).

Establishment of acute toxoplasmosis
------------------------------------

In this study, animal model of acute toxoplasmosis was established as described elsewhere ([@B13]). Briefly, the groups of mice were inoculated intraperitonealy with 1×10^4^ tachyzoite of *T. gondii,* RH strain.

Prophylactic effects of B. persicum essential oil
-------------------------------------------------

To evaluate prophylactic effects of *B. persicum* essential oil on acute toxoplasmosis in mice, two groups of mice were received *B. persicum* essential oil at the concentrations of 0.05 and 0.1 mL/kg for 14 days*.* A group of mice was used as control that received olive oil for 14 days; while another group was contained uninfected and untreated mice. After 24 h. (fifteenth day) mice in each group were infected intraperitonealy with 1×10^4^ tachyzoite of *T. gondii,* RH strain. To determine the prophylactic effects of *B. persicum* essential oil, the time/mean time of death in all infected mice was recorded. In addition, the number of parasites (tachyzoites) isolated from peritonea of infected mice were counted under light microscope by neubauer slide.

Therapeutic effects of B. persicum oil
--------------------------------------

In order to investigate therapeutic effects of *B. persicum* essential oil against acute toxoplasmosis in mice, at first, 3 groups of mice were infected intraperitonealy with 1×10^4^ tachyzoite of *T. gondii,* RH strain. After 24 h, two groups of mice were received *B. persicum* oil at the concentrations of 0.05 and 0.1 mL/kg two times a day for 5 days. A group of mice was used as control that received olive oil for 14 days; while another group was contained uninfected and untreated mice. To assess the treatment effects of *B. persicum* essential oil, the time/mean time of death in all infected mice were recorded. Furthermore, the number of parasites (tachyzoites) isolated from peritonea of infected mice were counted under light microscope by neubauer slide.

Statistical analysis
--------------------

Data analysis was carried out using SPSS statistical package version 17.0 (SPSS Inc., Chicago, IL, USA). Differences between test and control groups were analyzed by *t-*test. In addition, *P*\<0.05 was considered statistically significant.

Results
=======

GC/MS analysis of B. persicum oil
---------------------------------

[Table 1](#T1){ref-type="table"} indicates the results obtained by GC/MS analysis of *B. persicum* essential oil. Twenty-four compounds were identified in the *B. persicum* essential oil, which constitutes about 97.2% of this essential oil. The main components were γ-terpinene (46.1%), cuminaldehyde (15.5%), ϱ-cymene (6.7%) and limonene (5.9%).

###### Essential oil composition of *B. persicum* seeds identified by GC-MS

  **No**   **Components**            **KI [^a^](#TFN1){ref-type="table-fn"}**   **% Composition**
  -------- ------------------------- ------------------------------------------ -------------------
  1\.      α- Thujene                926                                        0.4
  2\.      α- Pinene                 936                                        2.7
  3\.      Sabinene                  968                                        1.0
  4\.      β -Pinene                 976                                        2.5
  5\.      Myrcene                   990                                        1.8
  6\.      ϱ -Cymene                 1016                                       6.7
  7\.      α-Terpinene               1019                                       1.3
  8\.      *σ* -Cymene               1021                                       0.2
  9\.      Limonene                  1029                                       5.9
  10\.     γ- Terpinene              1060                                       46.1
  11\.     α- Terpineolene           1087                                       0.9
  12\.     ϱ-Mentha-3-ene-7-al       1138                                       0.9
  13\.     Terpinene-4-ol            1160                                       0.2
  14\.     α- Terpineol              1168                                       2.2
  15\.     ϱ-Mentha-1,3 diene-7-al   1176                                       0.2
  16\.     Cuminaldehyde             1243                                       15.5
  17\.     Cuminyl alcohol           1265                                       7.4
  18\.     β- Caryophyllene          1419                                       0.2
  19\.     γ-Eleman                  1435                                       0.1
  20\.     β- Bisabolene             1478                                       0.5
  21\.     β- Selinene               1488                                       0.1
  22\.     Myristicin                1491                                       0.1
  23\.     Germacrene B              1558                                       0.1
  24\.     Dillapiol                 1631                                       0.2
           Total                                                                97.2

Kovats index on non-polar DB-5 ms column in reference to n-alkanes

Prophylactic effects of B. persicum essential oil
-------------------------------------------------

[Figure 2](#F2){ref-type="fig"} indicates prophylactic effects of *B. persicum* essential oil against acute toxoplasmosis in mice model.
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The time/mean time of death of infected mice was 100%, 8 and 9 days after oral administration of *B. persicum* essential oil at the concentration of 0.05 and 0.1 ml/kg, respectively, while this value for control group was 5 days. In addition, mean number of tachyzoites was 192 × 10^4^ and 64 × 10^4^ for infected mice treated with 0.05 and 0.1 ml/kg, respectively, whereas in control group, the mean number of tachyzoites was 288×10^4^ parasite. The obtained findings demonstrated that the difference in the time/mean time of death between of *B. persicum* oil at the concentration of 0.05 and 0.1 ml/kg and the control group was statistically significant (*P*\<0.05), whereas, the difference in mean number of tachyzoites between *B. persicum* oil at the concentration of 0.05 ml/kg and the control group was not statistically significant.

Therapeutic effects of B. persicum oil
--------------------------------------

As shown in [Fig. 3](#F3){ref-type="fig"}, 100% the time/mean time of death of infected mice was observed 7 and 8 days after oral administration of *B. persicum* essential oil at the concentration of 0.05 and 0.1 ml/kg, respectively, whereas the time/mean time of death of infected mice in control group was 100% in the fifth day. The mean number of tachyzoites was 189 × 10^4^ and 133 × 10^4^ for infected mice treated with 0.05 and 0.1 ml/kg, respectively, while in control group, the mean number of tachyzoites was 412×10^4^ parasite.
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Results exhibited that the difference in the time/mean time of death between of *B. persicum* essential oil at the concentration of 0.1 ml/kg and the control group was statistically significant (*P*\<0.05). The difference in mean number of tachyzoites between infected mice received *B. persicum* essential oil and the control group was statistically significant (*P*\<0.05).

Discussion
==========

This study was aimed to assess in vivo prophylactic and therapeutic effects of *B. persicum* essential oil against acute toxoplasmosis in mice. Since last centuries, plants and their derivatives have been used as a valuable natural resource for traditional remedies ([@B5]). In recent years, development of dire effects and microbial resistance to the chemically synthesized medication has caused changes in the situation and interest in the field of ethnobotanical research ([@B5]).

Our findings showed that oral administration of *B. persicum* oil for 14 days especially at the concentration of 0.1 ml/kg had potent prophylactic effects against acute toxoplasmosis in mice and their survival was prolonged to 9 days, while all mice in the control group died after fifth day*.* Moreover*,* treatment of infected mice by oral administration of *B. persicum* essential oil for 5 days revealed remarkable therapeutic effects against acute toxoplasmosis. So that *B. persicum* essential oil at the concentrations of 0.05 and 0.1 ml/kg significantly reduced the time/mean time of death and the mean tachyzoites in infected mice.

So far, various pharmacological activities such as antioxidant, anti-inflammatory, and antimicrobial effects have been related to *B. persicum* seeds. In the GC/MS analysis of the *B. persicum* essential oil, the main components were found to be hydrocarbon and oxygenated monoterpenes including γ-terpinene (46.1%), cuminaldehyde (15.5%), *ϱ*-cymene (6.7%) and limonene (5.9%). Various studies revealed potent antibacterial, antifungal and antiparasitic activities of these compounds such as terpenic derivates, γ-terpinene, carvacrol, *P*-cymene, thymol, carvone, and limonene ([@B14]--[@B18]). Therefore, phytoconstituents in these plants could be responsible for their antitoxoplasmosis activity though their exact mode of action especially immunemodulatory effects is poorly understood. However, in the case of antimicrobial mechanism of some terpenoids compounds, Sikkema et al. ([@B19]) have reported that these components diffuse into pathogen and damage cell membrane structures. On the other hand, the antimicrobial activity is related to ability of terpenes to affect not only permeability but also other functions of cell membranes, these compounds might cross the cell membranes, thus penetrating into the interior of the cell and interacting with critical intracellular sites ([@B20], [@B21]). Concerning toxicity effects, Mandegari et al ([@B22]) have shown that the *B. persicum* essential oil had no mortality up to the dose of 2.5 ml/kg. According to a toxicity classification, the *B. persicum* showed no significant toxicity against male NMRI mice ([@B23]).

Conclusion
==========

Findings revealed the remarkable therapeutic and prophylactic efficacy of the *B. persicum* essential oil against acute toxoplasmosis in mice model. Results also provided the scientific evidence that natural plants could be used in traditional medicine for the prevention and treatment of parasitic infections. However, further studies are required to evaluate exact effect of *B. persicum* essential oil particularly its immunomodulatory on acute toxoplasmosis.
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